Standard BioTools, Inc.

How big is Standard BioTools, Inc.?

As of Jun 18, Standard BioTools, Inc. has a market capitalization of 387.42 million, with net sales of 169.69 million and a net profit of -132.76 million over the latest four quarters. Shareholder's funds are 471.72 million, and total assets are 612.34 million as of Dec 24.

As of Jun 18, Standard BioTools, Inc. has a market capitalization of 387.42 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 169.69 million, while the sum of Net Profit for the same period is -132.76 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 471.72 million and Total Assets at 612.34 million.

What does Standard BioTools, Inc. do?

Standard BioTools, Inc. develops and commercializes life science tools for single-cell analysis and genomics. As of March 2025, it reported net sales of $41 million and a net loss of $26 million, with a market cap of $387.42 million.

Overview:<BR>Standard BioTools, Inc. operates in the Pharmaceuticals & Biotechnology industry, focusing on the development, manufacturing, and commercialization of life science tools, particularly for single-cell analysis and genomics applications.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 41 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -26 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 387.42 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.55 <BR>Return on Equity: -24.43% <BR>Price to Book: 0.85<BR><BR>Contact Details:<BR>Address: 7000 Shoreline Ct Ste 100, SOUTH SAN FRANCISCO CA: 94080-7603 <BR>Tel: 1 650 2666000 <BR>Website: https://www.fluidigm.com/

Should I buy, sell or hold Standard BioTools, Inc.?

Who are in the management team of Standard BioTools, Inc.?

As of March 2022, the management team of Standard BioTools, Inc. includes Dr. Carlos Paya (Independent Chairman), Mr. Stephen Linthwaite (President and CEO), and several Independent Directors: Ms. Ana Stankovic, Mr. Nicolas Barthelemy, Mr. Gerhard Burbach, Ms. Laura Clague, and Dr. Bill Colston. They oversee the company's strategic direction and governance.

As of March 2022, the management team of Standard BioTools, Inc. includes the following individuals:<BR><BR>- Dr. Carlos Paya, who serves as the Independent Chairman of the Board.<BR>- Mr. Stephen Linthwaite, who is the President, Chief Executive Officer, and a Director.<BR>- Ms. Ana Stankovic, who is a Director.<BR>- Mr. Nicolas Barthelemy, who is an Independent Director.<BR>- Mr. Gerhard Burbach, who is also an Independent Director.<BR>- Ms. Laura Clague, who serves as an Independent Director.<BR>- Dr. Bill Colston, who is another Independent Director.<BR><BR>This team is responsible for guiding the strategic direction and governance of the company.

Is Standard BioTools, Inc. technically bullish or bearish?

As of October 10, 2025, Standard BioTools, Inc. shows a mildly bullish trend overall, supported by weekly and monthly MACD indicators, despite mixed signals from Bollinger Bands and KST.

As of 10 October 2025, the technical trend for Standard BioTools, Inc. has changed from mildly bearish to mildly bullish. The weekly and monthly MACD indicators are both mildly bullish, supporting the positive shift in trend. The daily moving averages also indicate a mildly bullish stance. However, the Bollinger Bands show a mixed signal with a mildly bullish weekly view but a bearish monthly perspective. The KST is mildly bearish on the weekly and bearish on the monthly, while the OBV is bullish on the monthly but mildly bearish on the weekly. Overall, the technical stance is mildly bullish, albeit with some mixed signals. There is no available multi-period return data for comparison with the S&P 500.